U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Austin Vapor - 612956 - 06/02/2021
  1. Warning Letters

CLOSEOUT LETTER

Austin Vapor MARCS-CMS 612956 —

Delivery Method:
VIA Electronic Mail
Reference #:
RW2101474
Product:
Tobacco
Recipient:
Recipient Name
Michael Laughlin and Justin Laughlin
Austin Vapor

United States

michaeldlaughlin@gmail.com
jklaughlin@gmail.com
Issuing Office:
Center for Tobacco Products

United States

Dear Michael Laughlin and Justin Laughlin:

The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions included in your responses dated February 12, 2021, February 26, 2021, and March 26, 2021 in response to our Warning Letter dated January 29, 2021. Based on our evaluation, it appears that you have taken steps to address the violations contained in the Warning Letter regarding your website https://www.austinvapor.com.

However, our surveillance shows you continue to offer for sale to customers in the United States other tobacco products that may be subject to market authorization requirements. FDA encourages you to discuss with your suppliers the current status of any particular tobacco product’s marketing application or any product’s marketing authorization. For additional information regarding currently marketed tobacco products that a company generally might manufacture, distribute, or sell without risking FDA enforcement, please visit our website https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/deemed-new-tobacco-product-applications-lists?utm_medium=email&utm_source=govdelivery#list%20of%20deemed.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.

Sincerely,
/S/
David Rice
Branch Chief
Division of Promotion, Advertising, and Labeling
Office of Compliance and Enforcement
Center for Tobacco Products

VIA Electronic Mail

cc:

Cloudflare, Inc.
abuse@cloudflare.com

Contact Privacy Inc. Customer 1241107912
xxp6abeazo4i@contactprivacy.email

Google LLC
registrar-abuse@google.com

Back to Top